Patients with systemic lupus erythematosus and haematological malignancy at a tertiary care centre: timing, histopathology and therapy

摘要: Objectives: Patients with systemic lupus erythematosus (SLE) are at higher risk of haematological malignancies (HMs) than the general population. Most reports have focused on HM diagnosed after SLE, and excluded concurrent preceding diagnoses. Information response to therapy is also limited. Methods: We identified 13 296 cases 10 539 potential patients SLE our centre; 45 were confirmed SLE. Our retrospective case series was based these patients. Results: Of patients, 64% ≥1 year diagnosis 36% before or 29 had diffuse large B cell lymphoma (DLBCL), 6 indolent lymphoma, 4 leukaemia, 3 Hodgkin’ sd isease, 1e ach Burkitt’s T multiple myeloma. Eleven DLBCL treated cyclophosphamide, hydroxydaunorubicin, oncovin prednisone (CHOP) rituximab-CHOP; prednisone; only four achieved durable remission. 16 9 more 2 years tended be in remission prior diagnosis. Seven concurrently; terms their HM, six stable disease. Conclusions: In summary, most common type SLE; presented advancedstage disease poor outcomes. contrast, early stage typically